🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  2. Lapatinib

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule completed

    1 trial

  3. Lapatinib

    Novartis Pharmaceuticals

    Neoplasms, Breast

    phase 3 small molecule terminated

    2 trials

  4. Laquinimod

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  5. Laquinimod

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  6. Laquinimod

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    3 trials

  7. Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab

    Eli Lilly Co.

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    phase 3 small molecule active

    1 trial

  8. Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE

    Eli Lilly Co.

    Perennial Allergic Rhinitis (PAR)

    phase 3 small molecule active

    1 trial

  9. Leflunomide Mylan 10 mg, filmomhulde tabletten, PLACEBO

    Disc Medicine

    polymyalgia rheumatica

    phase 3 small molecule active

    1 trial

  10. Lenvatinib

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  11. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule terminated

    1 trial

  12. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 small molecule active

    1 trial

  13. Leuprorelin SR

    Takeda

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

  14. Levetiracetam NORMON 250 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 250 mg, Levetiracetam NORMON 500 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 500 mg

    The George Institute

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial

  15. Levetiracetam XR, Masked Keppra® placebo film-coated tablets (a placebo tablet inside a capsule), Keppra 500 mg film-coated tablets, Levetiracetam prolonged-release placebo granules

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial

  16. Levodopa

    Lxo Ireland Designated Activity Company

    Ischaemic Stroke

    phase 3 small molecule completed

    1 trial

  17. Levosimendan, The levosimendan placebo drug product is an immediate-release dosage form for oral administration.

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)

    phase 3 small molecule active

    1 trial

  18. Levotiroxina Teva 25 microgrammi compresse

    Fondazione Telethon ETS

    Hodgkin and non Hodgkin lymphoma, Medulloblastoma

    phase 3 small molecule active

    1 trial

  19. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations

    phase 3 small molecule active

    1 trial

  20. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD)

    phase 3 small molecule active

    1 trial

  21. Lidocaine spray

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Uterine Cervical Dysplasia

    phase 3 other completed

    1 trial

  22. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  23. Linaclotide or Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  24. Linvoseltamab

    Regeneron UK Limited

    Relapsed and/or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources